ALTIRATINIB (DCC-2701)
Background Information: Abstract (Ref 1): Altiratinib (DCC-2701) was designed based on the rationale of engineering a single therapeutic agent able to address multiple hallmarks of cancer. Specifically, Altiratinib inhibits not only mechanisms of tumor initiation and...
LYC-55716 (CINTIRORGON)
Cintirorgon (CAS No.: 2055536-64-4), is a first-in-class, selective and orally bioavailable RORγ agonist. Cintirorgon (LYC-55716) modulates gene expression of RORγ expressing T lymphocyte immune cells, resulting in enhanced effector function, as well as decreased immunosuppression,...
Darovasertib (LXS-196, NVP-LXS196, IDE196)
Darovasertib (CAS No.: 1874276-76-2), is a potent, selective and orally active protein kinase C (PKC) inhibitor, with IC50 values of 1.9 nM, 0.4 nM and 3.1 μM for PKCα, PKCθ and GSK3β, respectively. Darovasertib has...